# A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting

Study · id `cardio:ct-nct07613307` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07613307](<https://clinicaltrials.gov/study/NCT07613307>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07613307

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 130 participants.

## Technical summary

Registry record NCT07613307. Allocation not applicable; no masking; primary purpose treatment. Start 2026-07-15 (actual); primary completion 2027-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 130 participants (planned count; ClinicalTrials.gov record NCT07613307, source copy `cardio:ctgov-nct07613307-2026-10-08`, retrieved 2026-10-26)
- Started: 2026-07-15 (actual) (ClinicalTrials.gov record NCT07613307, source copy `cardio:ctgov-nct07613307-2026-10-08`, retrieved 2026-10-26)
- Primary completion: 2027-05 (anticipated) (ClinicalTrials.gov record NCT07613307, source copy `cardio:ctgov-nct07613307-2026-10-08`, retrieved 2026-10-26)
- Completion: 2027-05 (anticipated) (ClinicalTrials.gov record NCT07613307, source copy `cardio:ctgov-nct07613307-2026-10-08`, retrieved 2026-10-26)
- Countries: India; Saudi Arabia; South Africa; United Arab Emirates (ClinicalTrials.gov record NCT07613307, source copy `cardio:ctgov-nct07613307-2026-10-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07613307-2026-10-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
- Acronym: ACHIEVE-RAM
- Condition: Diabetes Mellitus, Type 2
- Condition: Diabetes Melletus
- Condition: Glucose Metabolism Disorders
- Condition: Metabolic Disorders
- Condition: Nutritional and Metabolic Diseases
- Condition: Endocrine System Diseases
- Condition: Feeding Behavior
- Condition: Behavior
- Condition: Fasting
- Condition: Glucagon-Like Peptide-1 Receptor
- Condition: Glucagon-Like Peptide Receptors
- Condition: Receptors, G-Protein-Coupled
- Condition: Receptors, Cell Surface
- Condition: Membrane Proteins
- Condition: Proteins
- Condition: Receptors, Peptide
- Intervention (Drug): Orforglipron
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: ef90600f586931cdcbc18e5dd98efa996f53682ca11e029a73e32fe285fe8cbe
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
